Your browser doesn't support javascript.
loading
Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia.
Ramos Elbal, Eduardo; Fuster, José Luis; Campillo, José Antonio; Galera, Ana María; Cortés, Mar Bermúdez; Llinares, María Esther; Jiménez, Irene; Plaza, Mercedes; Banaclocha, Helios Martínez; Galián, José Antonio; Blanquer Blanquer, Miguel; Martínez Sánchez, María Victoria; Muro, Manuel; Minguela, Alfredo.
Affiliation
  • Ramos Elbal E; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Fuster JL; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Campillo JA; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Galera AM; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Cortés MB; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Llinares ME; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Jiménez I; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Plaza M; Pediatric Oncohematology Department, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Banaclocha HM; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Galián JA; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Blanquer Blanquer M; Haematology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Martínez Sánchez MV; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Muro M; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain.
  • Minguela A; Immunology Service, Clinic University Hospital Virgen de la Arrixaca and Biomedical Research Institute of Murcia Pascual Parrilla (IMIB), 30120, Murcia, Spain. alfredo.minguela@carm.es.
Clin Transl Oncol ; 25(5): 1446-1454, 2023 May.
Article in En | MEDLINE | ID: mdl-36598635
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Type of study: Observational_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Transl Oncol Year: 2023 Document type: Article Affiliation country: Spain Country of publication: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Type of study: Observational_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Clin Transl Oncol Year: 2023 Document type: Article Affiliation country: Spain Country of publication: Italy